

## National Institute for Health and Clinical Excellence

### 927 – Micropressure therapy for refractory Ménière's disease

#### Consultation Comments table

IPAC date: Thursday 13 October 2011

Com . no.	Consultee name and organisation	Sec. no.	Comments	Response Please respond to all comments
1	Consultee 1 Specialist Adviser	1	sensible recommendations	Thank you for your comment.
2	Consultee 2 Specialist Society	1	The Royal College of Physicians is grateful for the opportunity to respond to this consultation. Overall, our experts agree with the provisional recommendations.	Thank you for your comment.
3	Consultee 3 Medtronic Manufacturer	1	We would wish to point out that technology is neither new nor novel at this time as it has been available in the UK since 2003. The procedure is for difficult to treat patients who have disabling symptoms. The safety concerns expressed should be set against the potential benefits in this disabling condition.	Thank you for your comment. The Committee has acknowledged the lack of efficacious alternatives and the potential usefulness of this technology if proven to be effective in section 2.5.1 of the guidance. It did not wish to add any further comment to this.

<b>Com . no.</b>	<b>Consultee name and organisation</b>	<b>Sec. no.</b>	<b>Comments</b>	<b>Response</b> Please respond to all comments
4	Consultee 1 Specialist Adviser	<b>2.1</b>	The most commonly used and the least invasive of surgical management is not included here. Gentamicin based vestibular ablation where the drug is infiltrated in the middle ear as an office procedure. The other three above mentioned and recognised procedures are invasive and make the micropressure therapy look attractive in contrast.	Thank you for your comment. Section 2.1.2 of the guidance will be changed to include 'gentamicin vestibular ablation'.
5	Consultee 1 Specialist Adviser	<b>2.2</b>	appropriately described	Thank you for your comment.
6	Consultee 1 Specialist Adviser	<b>2.3</b>	no issues	Thank you for your comment.
7	Consultee 1 Specialist Adviser	<b>2.4</b>	factual error: loss of ventilation tube in the MIDDLE ear	Thank you for your comment. Section 2.4.3 of the guidance is the opinion of the Specialist Advisers and will be changed to note loss of the ventilation tube in the middle ear rather than the inner ear.
8	Consultee 3 Medtronic Manufacturer	<b>2.4</b>	The procedure is for difficult to treat patients who have disabling symptoms. The safety concerns expressed should be set against the potential benefits in this disabling condition where there are few alternatives.	Thank you for your comment. The Committee has acknowledged the lack of efficacious alternatives and the potential usefulness of this technology if proven to be effective in section 2.5.1 of the guidance.
9	Consultee 3 Medtronic Manufacturer	<b>2.5</b>	As the committee has noted the course of Menieres disease is variable and for this reason it will be difficult to get unequivocal evidence. This procedure is for the resistant difficult to treat cases and the outcomes from the limited numbers of studies show benefit.	Thank you for your comment. Section 2.5.2 of the guidance acknowledges the difficulties of evidence development for this technology.

*"Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees."*